Page last updated: 2024-12-06

dibromothymoquinone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Dibromothymoquinone (DBTQ) is a synthetic derivative of thymoquinone, a natural compound found in black seed oil. It exhibits various biological activities, including antioxidant, anti-inflammatory, and anticancer properties. DBTQ is synthesized through bromination of thymoquinone, and its efficacy has been studied in various in vitro and in vivo models. It has been shown to suppress the growth of various cancer cell lines, including breast, prostate, and lung cancer. The mechanism of action of DBTQ is attributed to its ability to induce apoptosis (programmed cell death) and inhibit the proliferation of cancer cells. DBTQ also exhibits anti-inflammatory effects by suppressing the production of inflammatory mediators, such as cytokines. The potential of DBTQ as a therapeutic agent is under investigation, and further studies are needed to evaluate its safety and efficacy in humans.'
```

Dibromothymoquinone: At low concentrations, this compound inhibits reduction of conventional hydrophilic electron acceptors, probably acting as a plastoquinone antagonist. At higher concentrations, it acts as an electron acceptor, intercepting electrons either before or at the site of its inhibitory activity. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID34474
CHEMBL ID1231418
CHEBI ID19371
SCHEMBL ID919786
MeSH IDM0006255

Synonyms (39)

Synonym
CHEMBL1231418
2,5-dibromo-3-isopropyl-6-methylbenzo-1,4-quinone
29096-93-3
2,5-dibromo-3-methyl-6-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione
CHEBI:19371 ,
dibromothymoquinone
2,5-dibromo-3-methyl-6-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione
2,5-dibromo-3-methyl-6-(1-methylethyl)cyclohexa-2,5-diene-1,4-dione
DB04646
2,5-dibromo-3-isopropyl-6-methyl-1,4-benzoquinone
2,5-dibromo-3-isopropyl-6-methylbenzoquinone
2,5-dibromo-6-isopropyl-3-methyl-1,4-benzoquinone
dbmib
2,5-cyclohexadiene-1,4-dione, 2,5-dibromo-3-methyl-6-(1-methylethyl)-
2,5-dibromo-3-methyl-6-isopropyl-p-benzoquinone
2,5-dibromo-3-methyl-6-propan-2-ylcyclohexa-2,5-diene-1,4-dione
A819764
0by5ufn2u6 ,
unii-0by5ufn2u6
einecs 249-431-8
FT-0638830
AKOS015889026
SCHEMBL919786
p-mentha-3,6-diene-2,5-dione, 3,6-dibromo-
2,5-dibrome-6-isopropyl-3-methyl-1,4-benzoquinone
dbimb
GHHZELQYJPWSMG-UHFFFAOYSA-N
dibromothymolquinone
3,6-dibromothymoquinone
2,5-dibromo-3-methyl-6-isopropyl-1,4-benzoquinone
2,5-dibromothymoquinone
DTXSID60183343
SR-01000883712-1
sr-01000883712
J-017389
2,5-dibromo-3-methyl-6-isopropylbenzoquinone; dbmib
2-bromo-3-isopropyl-5,6-dimethyl-(1,4)benzoquinone
Q17539331
2,5-dibromo-3-isopropyl-6-methylcyclohexa-2,5-diene-1,4-dione

Research Excerpts

Effects

Dibromothymoquinone (DBMIB) has been used as a specific inhibitor of plastoquinol oxidation at the Q0 binding site of the cytochrome b6f complex for 40 years.

ExcerptReferenceRelevance
"Dibromothymoquinone (DBMIB) has been used as a specific inhibitor of plastoquinol oxidation at the Q0 binding site of the cytochrome b6f complex for 40 years. "( Re-evaluation of the side effects of cytochrome b6f inhibitor dibromothymoquinone on photosystem II excitation and electron transfer.
Belatik, A; Carpentier, R; Hotchandani, S; Joly, D, 2013
)
2.07
"Dibromothymoquinone has been shown to inhibit light-induced cytochrome b reduction, and oxidation of succinate and NADH by chromatophores of Rhodopseudomonas capsulata. "( The effect of dibromothymoquinone on respiratory and photosynthetic electron transport in Rhodopseudomonas capsulata chromatophores.
Evans, EH; Gooding, DA, 1976
)
2.06
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
cytochrome-b6f complex inhibitornull
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
1,4-benzoquinonesAny member of the class of benzoquinones that is 1,4-benzoquinone or its C-substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
nitrilotriacetate degradation222

Bioassays (6)

Assay IDTitleYearJournalArticle
AID1374919Growth inhibition of human OVCAR8 cells after 72 hrs by SRB assay2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
The synthesis and evaluation of thymoquinone analogues as anti-ovarian cancer and antimalarial agents.
AID1374921Selectivity index, ratio of IC50 for SV-40 immortalized human ovarian epithelial cells to IC50 for human A2780cis cells2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
The synthesis and evaluation of thymoquinone analogues as anti-ovarian cancer and antimalarial agents.
AID1374928Growth inhibition of SV-40 immortalized human ovarian epithelial cells after 72 hrs by SRB assay2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
The synthesis and evaluation of thymoquinone analogues as anti-ovarian cancer and antimalarial agents.
AID1374920Growth inhibition of human A2780cis cells after 72 hrs by SRB assay2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
The synthesis and evaluation of thymoquinone analogues as anti-ovarian cancer and antimalarial agents.
AID1374918Growth inhibition of human A2780 cells after 72 hrs by SRB assay2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
The synthesis and evaluation of thymoquinone analogues as anti-ovarian cancer and antimalarial agents.
AID1374922Antiplasmodial activity against Plasmodium falciparum Dd2 by SYBR Green I fluorescence assay2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
The synthesis and evaluation of thymoquinone analogues as anti-ovarian cancer and antimalarial agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (131)

TimeframeStudies, This Drug (%)All Drugs %
pre-199067 (51.15)18.7374
1990's12 (9.16)18.2507
2000's33 (25.19)29.6817
2010's17 (12.98)24.3611
2020's2 (1.53)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 14.72

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index14.72 (24.57)
Research Supply Index4.92 (2.92)
Research Growth Index4.46 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (14.72)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other136 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]